0.03
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Entropy Neurodynamics
Its shares trade on ASX under the ticker ENP.AX. It has been listed since 18 December 2018. In the fiscal year to 30 June 2025, it reported revenue of A$1.6m and a net loss of A$5.3m. At that date it held total assets of A$6.7m and shareholders' equity of A$6.0m.
Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm invests in biopharmaceutical drug development. The firm is engaged in exosome technology and holds a portfolio of intellectual property and know-how related to exosomes and the manufacture of exosomes. The Company’s exosome technologies solve needs for the success of exosome medicines, LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies. The firm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome delivery for their own products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Dec 2018
- Website
- exopharm.com ↗
Leadership
Pay as last reported
- Mr. Herwig JanssenNon-Executive Chairman of the Board
- Mr. Jason CarrollChief Executive Officer, Director, since 2023
- Mr. Hamish GeorgeChief Financial Officer, Company Secretary
- Mr. Christopher NtoumenopoulosExecutive Director, since 2024
- Mr. Clarke BarlowNon-Executive Director
- Mr. Gage JullNon-Executive Director
- Mr. Daniel TilletNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Exopharm Ltd. develops exosome therapies for biopharmaceutical applications in Melbourne, Australia.
- The company holds a portfolio of intellectual property related to exosome technology and manufacturing.
- Exopharm's LEAP manufacturing technology solves key challenges in exosome medicine production.
Weaknesses
- Exopharm Ltd. has no commercialized products as of 2023.
- The company's IPO was in 2018, indicating limited market history.
- Exopharm's focus on exosome technology may limit diversification.
Opportunities
- Exopharm can expand its exosome technology applications in the Health Care sector.
- The biotechnology industry in Australia offers growth potential for Exopharm.
- Exopharm's LOAD API loading technology could be licensed to pharmaceutical companies.
Threats
- Exopharm faces competition from other biotechnology firms in the Health Care sector.
- Regulatory challenges may impact exosome therapy development in Australia.
- The biotechnology sector requires significant capital investment for research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.